Search results for "OUTCOME"

showing 10 items of 5148 documents

A rare case of Prinzmetal angina 3 days after coronary artery stenting with a second-generation drug-eluting stent

2015

Non previsto.

Angina Pectoris VariantMaleCoronary angiographymedicine.medical_specialtyTime FactorsVasodilator Agentsmedicine.medical_treatmentCoronary VasospasmPrinzmetal angina coronary artery stenting stent second-generation drug-eluting stent.Coronary AngiographyProsthesis DesignBalloonAnginaAngioplastyInternal medicineRare caseHumansMedicineEverolimusAngioplasty Balloon CoronarySirolimusEverolimusbusiness.industryCoronary StenosisCardiovascular AgentsDrug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareTreatment Outcomemedicine.anatomical_structureDrug-eluting stentCardiologyPrinzmetal angina coronary artery stentingdrug-eluting stentCardiology and Cardiovascular Medicinebusinessmedicine.drugArteryCoronary Artery Disease
researchProduct

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

2015

Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results— We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of med…

Angiotensin receptorVascular damage Radboud Institute for Health Sciences [Radboudumc 16]receptorsTetrazolesheart failureAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateSacubitrilAngiotensin; Heart failure; Neprilysin; Receptors; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Disease Progression; Medicine (all); Cardiology and Cardiovascular Medicine; Physiology (medical)AngiotensinEnalaprilRisk FactorsEnalapril/therapeutic useNatriuretic Peptide BrainHeart Failure/bloodSurvivorsReceptorNeprilysinAminobutyrates: Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine]Troponin/bloodTroponinAngiotensin Receptor Antagonists/therapeutic useDrug CombinationsAngiotensin-Converting Enzyme Inhibitors/therapeutic useTreatment OutcomeTetrazoles/therapeutic useCardiologyDisease ProgressionValsartanNeprilysinHeart Failure/blood/drug therapy/physiopathologyCardiology and Cardiovascular Medicinemedicine.drugReceptormedicine.medical_specialtyHeart failureneprilysinAngiotensin Receptor Antagonistsreceptors angiotensinDouble-Blind MethodPhysiology (medical)Internal medicineRenin–angiotensin systemmedicineHumansheart failure neprilysin receptors angiotensinEnalaprilbusiness.industryBiphenyl CompoundsStroke Volumemedicine.diseasePeptide FragmentsEndocrinologyAminobutyrates/therapeutic useStroke Volume/physiologyHeart failureNatriuretic Peptide Brain/blood: Cardiovascular & respiratory systems [D03] [Human health sciences]businessNeprilysin/antagonists & inhibitorsPeptide Fragments/bloodSacubitril ValsartanBiomarkersBiomarkers/blood
researchProduct

Role of ARBs in the blood hypertension therapy and prevention of cardiovascular events

2009

Hypertension has a worldwide high incidence in the general population and undoubtedly it is the most important risk factor for cardiovascular morbidity and mortality, in industrialized countries. In this Review we investigated the role of angiotensin II receptor antagonists (ARBs) therapy in the treatment of essential hypertension. We selected in the PubMed and in a list of selected sources the most significant clinical trials and meta-analysis carried out from 1999 to now, to assess, in adult patients populations, ARBs efficacy, safety and tolerability profile, in comparison with the efficacy of the other common antihypertensive drugs, with particular regard to both the prevention of disab…

Angiotensin receptormedicine.medical_specialtyHeart DiseasesCost-Benefit AnalysisClinical BiochemistryPopulationPeptidyl-Dipeptidase AEssential hypertensionAngiotensin Receptor AntagonistsInternal medicineDrug DiscoverymedicineHumansRisk factoreducationAntihypertensive AgentsPharmacologyeducation.field_of_studyClinical Trials as TopicAngiotensin Receptor Antagonistsbusiness.industrymedicine.diseaseClinical trialCerebrovascular DisordersTreatment OutcomeTolerabilityARB blood hypertension cardiovascular eventsHeart failureHypertensionCardiologyMolecular Medicinebusiness
researchProduct

Changes in Body Composition in Anorexia Nervosa : Predictors of Recovery and Treatment Outcome

2015

The restoration of body composition (BC) parameters is considered to be one of the most important goals in the treatment of patients with anorexia nervosa (AN). However, little is known about differences between AN diagnostic subtypes [restricting (AN-R) and binge/purging (AN-BP)] and weekly changes in BC during refeeding treatment. Therefore, the main objectives of our study were twofold: 1) to assess the changes in BC throughout nutritional treatment in an AN sample and 2) to analyze predictors of BC changes during treatment, as well as predictors of treatment outcome. The whole sample comprised 261 participants [118 adult females with AN (70 AN-R vs. 48 AN-BP), and 143 healthy controls].…

Anorexia Nervosa:Psychiatry and Psychology::Mental Disorders::Eating Disorders::Binge-Eating Disorder [Medical Subject Headings]Body water:Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]lcsh:MedicineÍndice de masa corporalAnorexia nervosaMetabolismo basal:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]FatsImpedancia eléctricaadolescentslcsh:Science:Psychiatry and Psychology::Mental Disorders::Eating Disorders::Anorexia Nervosa [Medical Subject Headings]eating-disordersBody mass indexMetasMultidisciplinaryBulimia nervosaFemeninoAnorèxia nerviosaTrastorno por atracónModelos logísticos:Anatomy::Tissues::Connective Tissue::Adipose Tissue [Medical Subject Headings]HumanosTreatment OutcomeBasal metabolic rate measurementfat distributionbioelectrical-impedanceBody CompositionEating disordersObesitatFemalewomenmedicine.symptomBioelectrical impedance analysisResearch ArticleAdultTejido adiposomedicine.medical_specialtyPatient Dropoutsweight-gainwaterPes corporal:Anatomy::Fluids and Secretions::Body Fluids::Body Water [Medical Subject Headings]Anorexia nerviosa:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Motivation::Goals [Medical Subject Headings]Internal medicine:Health Care::Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Outcome and Process Assessment (Health Care)::Outcome Assessment (Health Care)::Treatment Outcome [Medical Subject Headings]medicineTreatment guidelinesHumansObesityComposición corporal:Health Care::Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Models Statistical::Logistic Models [Medical Subject Headings]Trastorns de la conducta alimentàriabusiness.industrylcsh:Renergy-expenditureduration:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques Endocrine::Thyroid Function Tests::Basal Metabolism [Medical Subject Headings]:Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Body Composition [Medical Subject Headings]Anorexia nervosaBody weightmedicine.diseaseObesityAgua corporalEndocrinology:Check Tags::Female [Medical Subject Headings]Bulimia nervosaCase-Control StudiesBasal metabolic ratelcsh:QResultado del tratamiento:Phenomena and Processes::Physical Phenomena::Magnetic Phenomena::Electromagnetic Phenomena::Electricity::Electric Conductivity::Electric Impedance [Medical Subject Headings]businessBody mass indexWeight gain
researchProduct

Factors leading to dissemination of cutaneous anthrax: an international ID-IRI study

2022

Background: Although anthrax is a rare zoonotic infection, it still causes significant mortality and morbidity. In this multicenter study, which is the largest anthrax case series ever reported, we aimed to describe the factors leading to dissemination of cutaneous anthrax.Methods: Adult patients with cutaneous anthrax from 16 referral centers were pooled. The study had a retrospective design, and included patients treated between January 1, 1990 and December 1, 2019. Probable, and confirmed cases based upon CDC anthrax 2018 case definition were included in the study. A descriptive statistical analysis was performed for all variables.Results: A total of 141 cutaneous anthrax patients were i…

AnthraxGastrointestinalMeningitiInfectious DiseasesOutcome.MeningitisBacteremiaMortalityMicrobiologyOutcome
researchProduct

Low dosage liposomal amphotericin B in the treatment of Candida infections in critically ill patients.

2011

Antifungal AgentsTreatment OutcomeCritical care candida sepsisAmphotericin BCritical IllnessCandidiasisHumansSettore MED/41 - AnestesiologiaPilot ProjectsAmphotericin B; administration /&/ dosage Antifungal Agents; administration /&/ dosage Candidiasis; drug therapy Critical Illness Humans Middle Aged Pilot Projects Treatment OutcomeMiddle Agedadministration /&/ dosagedrug therapy
researchProduct

Nephrotoxicity in the setting of invasive fungal diseases

2008

Amphotericin B, a broad spectrum antifungal agent, is widely used despite significant adverse events including nephrotoxicity. Nephrotoxicity occurs frequently in patients receiving amphotericin B. Different definitions for nephrotoxicity are reviewed in the context of outcome in patients with invasive fungal diseases. In most publications, mortality was higher in patients experiencing nephrotoxicity and mean hospital length of stay was prolonged. As a consequence, the use of less nephrotoxic antifungal agents could improve treatment outcomes.

Antifungalmedicine.medical_specialtyAntifungal Agentsmedicine.drug_classTreatment outcomeLength of hospitalizationContext (language use)DermatologyNephrotoxicityImmunocompromised HostAmphotericin BAmphotericin BmedicineHumansIn patientIntensive care medicineAdverse effectbusiness.industryGeneral MedicineLength of StayTreatment OutcomeInfectious DiseasesMycosesKidney Diseasesbusinessmedicine.drugMycoses
researchProduct

Adjunctive Brivaracetam in Older Patients with Focal Seizures: Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST).

2022

BACKGROUND: The management of epilepsy in older adults has become part of daily practice because of an aging population. Older patients with epilepsy represent a distinct and more vulnerable clinical group as compared with younger patients, and they are generally under-represented in randomized placebo-controlled trials. Real-world studies can therefore be a useful complement to characterize the drug's profile. Brivaracetam is a rationally developed compound characterized by high-affinity binding to synaptic vesicle protein 2A and approved as adjunctive therapy for focal seizures in adults with epilepsy. OBJECTIVE: The aim of this study was to assess the 12-month effectiveness and tolerabil…

Antiseizure medicationEpilepsySettore MED/26PyrrolidinonesFocal seizuresTreatment OutcomeDrug TherapyDouble-Blind MethodItalySeizuresBrivaracetamCombinationAntiseizure medication; Brivaracetam; Focal seizuresAged; Double-Blind Method; Drug Therapy Combination; Humans; Italy; Pyrrolidinones; Retrospective Studies; Seizures; Treatment Outcome; Anticonvulsants; EpilepsyHumansPharmacology (medical)Settore MED/26 - NeurologiaAnticonvulsantsDrug Therapy CombinationGeriatrics and GerontologyAgedRetrospective StudiesDrugsaging
researchProduct

Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study

2016

Background: Atrial fibrillation (AF) is associated with a substantial risk of thromboembolism and mortality, significantly reduced by oral anticoagulation. Adherence to guidelines may lower the risks for both all cause and cardiovascular (CV) deaths. Methods: Our objective was to evaluate if antithrombotic prophylaxis according to the 2012 European Society of Cardiology (ESC) guidelines is associated to a lower rate of adverse outcomes. Data were obtained from REPOSI; a prospective observational study enrolling inpatients aged ≥65 years. Patients enrolled in 2012 and 2014 discharged with an AF diagnosis were analysed. Results: Among 2535 patients, 558 (22.0 %) were discharged with a diagnos…

Antithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Cardiology and Cardiovascular MedicineMaleRegistrieTime Factorsantithrombotic therapy; atrial fibrillation; elderly; guidelines; outcomesAtrial fibrillation (AF)Practice PatternsKaplan-Meier Estimate030204 cardiovascular system & hematologyGuidelineoutcomesCoronary artery disease0302 clinical medicineElderlyRisk FactorsAtrial FibrillationAntithrombotic80 and overAge Factor030212 general & internal medicineRegistriesguidelinesAntithrombotic therapy Atrial fibrillation Elderly Guidelines OutcomesPractice Patterns Physicians'OutcomeAged 80 and overFibrinolytic AgentAge FactorsAtrial fibrillationGeneral MedicineTreatment OutcomeItalyAtrial fibrillation (AF) thromboembolism antithrombotic prophylaxisPractice Guidelines as TopicCardiologyFemaleGuideline AdherenceCardiology and Cardiovascular MedicineHumanAntithrombotic therapy; Atrial fibrillation; Elderly; Guidelines; Outcomes; Age Factors; Aged; Aged 80 and over; Atrial Fibrillation; Chi-Square Distribution; Female; Fibrinolytic Agents; Guideline Adherence; Humans; Italy; Kaplan-Meier Estimate; Logistic Models; Male; Practice Patterns Physicians'; Proportional Hazards Models; Registries; Risk Assessment; Risk Factors; Thromboembolism; Time Factors; Treatment Outcome; Practice Guidelines as Topic; Cardiology and Cardiovascular Medicinemedicine.medical_specialtyLogistic ModelTime FactorSocio-culturaleLower riskRisk Assessment03 medical and health sciencesFibrinolytic AgentsInternal medicineThromboembolismmedicineHumansProportional Hazards ModelsAgedAntithrombotic therapyPhysicians'Chi-Square Distributionbusiness.industryProportional hazards modelRisk FactorSettore MED/09 - MEDICINA INTERNAGuidelinethromboembolismmedicine.diseaseAtrial fibrillationLogistic ModelsProportional Hazards Modelantithrombotic prophylaxisbusinessChi-squared distributionFibrinolytic agent
researchProduct

The HCV Sicily Network: A web-based model for the management of HCV chronic liver diseases

2016

Epidemiological studies report that in Sicily reside about 30,000 citizens with a diagnosis of chronic hepatitis due to HCV. The availability of direct antiviral action (DAA) is a real therapeutic breakthrough, but the high cost of the therapeutic regimes limits their use and forced the National Health System to establish clinical priority for the treatment.The HCV Sicily Network is a web-based model of best medical practice, which was designed to improve the management and the treatment of HCV chronic hepatitis and cirrhosis. The network includes 41 centers and 84 gastroenterologists or infectivologists connected by a web platform that recorder the diagnosis and the clinic priority for the…

Antiviral AgentMaleInternetHepaciviruHepatitis C virusInterferon-alphaDirect antiviral agent drugs (DAA); Hepatitis C virus; Web-based network; Pharmacology (medical)HepacivirusHepatitis C ChronicMiddle AgedWeb-based network; Hepatitis C virus; Direct antiviral agent drugs (DAAAntiviral AgentsCommunity NetworksTreatment OutcomeAntiviral Agents; Drug Therapy Combination; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Internet; Male; Middle Aged; Ribavirin; Sicily; Treatment Outcome; Community NetworksRibavirinHumansDirect antiviral agent drugs (DAADrug Therapy CombinationSicilyWeb-based networkHuman
researchProduct